Altimmune (NASDAQ:ALT) Earns Outperform Rating from Analysts at Leerink Partners

Equities research analysts at Leerink Partners assumed coverage on shares of Altimmune (NASDAQ:ALT) in a research note issued to investors on Monday, MarketBeat reports. The firm set an “outperform” rating and a $10.00 price target on the stock. Leerink Partners’ target price points to a potential upside of 236.13% from the stock’s current price.

A number of other research analysts have also recently weighed in on ALT. Wall Street Zen cut shares of Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. William Blair restated a “market perform” rating on shares of Altimmune in a research note on Thursday, March 5th. Citizens Jmp lowered their price target on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Friday, March 27th. Finally, Truist Financial began coverage on Altimmune in a report on Wednesday, March 18th. They set a “buy” rating and a $12.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $15.71.

Altimmune Stock Performance

Shares of Altimmune stock traded up $0.28 during trading hours on Monday, hitting $2.98. 733,636 shares of the company’s stock traded hands, compared to its average volume of 4,210,808. The stock has a market capitalization of $578.55 million, a price-to-earnings ratio of -3.22 and a beta of 0.21. Altimmune has a 12-month low of $2.56 and a 12-month high of $7.73. The company has a debt-to-equity ratio of 0.12, a current ratio of 29.56 and a quick ratio of 29.56. The company has a fifty day simple moving average of $2.96 and a 200-day simple moving average of $3.82.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. Equities research analysts anticipate that Altimmune will post -0.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ALT. Brown Wealth Management LLC grew its stake in Altimmune by 10.7% during the fourth quarter. Brown Wealth Management LLC now owns 258,673 shares of the company’s stock valued at $934,000 after acquiring an additional 25,000 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Altimmune by 21.9% in the 4th quarter. ProShare Advisors LLC now owns 20,816 shares of the company’s stock valued at $75,000 after purchasing an additional 3,735 shares during the period. SBI Securities Co. Ltd. boosted its holdings in Altimmune by 27.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after purchasing an additional 1,928 shares during the period. PKS Advisory Services LLC purchased a new position in shares of Altimmune during the 4th quarter valued at $55,000. Finally, Concurrent Investment Advisors LLC grew its position in shares of Altimmune by 10.4% during the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock valued at $96,000 after purchasing an additional 2,500 shares in the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.